Scott Campbell, PhD

Scott Campbell, PhD

Chief Executive Officer

Dr. Scott Campbell began his tenure as Chief Executive Officer of the Foundation in May 2015.  Prior to joining the Foundation, Dr. Campbell served as a Scientific Advisory Board member for Temptime Corporation and served as Executive Director and CEO of the Foundation for the National Institutes of Health.  He was responsible for overall leadership of the FNIH and was involved with many of the collaborative research projects funded through the FNIH including the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Biomarkers Consortium, the Observational Medical Outcomes Partnership (OMOP), Grand Challenges in Global Health, the US-Russia Scientific Forum and the mHealth Summit.  He also represented the Foundation on the Health Research Alliance and the Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation.  

From 2001-2010, Dr. Campbell served as National Vice President of Research Programs at the American Diabetes Association.  In addition to overseeing all research-related programs at the ADA, he also was responsible for helping acquire major donations to the ADA Research Foundation.  He was a trustee on the Board of Trustees, Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC); member of the IOM Clinical Research Roundtable; and served on the Board of Directors of the Health Research Alliance.  He also represented the ADA on several federally related committees, including the Diabetes Mellitus Interagency Coordinating Committee (DMICC) at the National Institutes of Health.  Before beginning his non-profit scientific administration career, Dr. Campbell spent 16 years in academia with academic appointments at the University of South Dakota, University of Missouri, and Michael Reese Hospital.

Scott received his PhD in Basic Biomedical Sciences from the University of South Florida.  He is the author of 40 peer-reviewed articles, 9 invited reviews, and 14 book chapters related to cardiovascular disease.

Previous Article Gabrielle Garcon, BS
Next Article Varleisha Gibbs, PhD, OTD, OTR/L